Damora Therapeutics, Inc. quarterly report, Q1 FY2026

Business Context and Reporting Period

Company: Damora Therapeutics, Inc. (formerly Galecto, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: A preclinical-stage biopharmaceutical company developing therapies for hematological malignancies, specifically myeloproliferative neoplasms (MPNs). The company focuses on a portfolio of mutant calreticulin (mutCALR) targeting product candidates: DMR-001, DMR-002, and DMR-003. In November 2025, the company completed an asset acquisition of "Pre-Acquisition Damora" and executed a significant PIPE transaction.

Key Financial Metrics

Metric (in thousands) Q1 2026 Q1 2025
Revenue $0 $0
Net Loss $(27,783) $(2,533)
Operating Expenses $30,811 $2,599
Research & Development (R&D) $23,777 $678
General & Administrative (G&A) $7,034 $1,921
Cash and Cash Equivalents (End of Period) $532,899 $11,939
Net Cash Used in Operating Activities $(20,598) $(2,439)
Net Cash Provided by Financing Activities $295,921 $0
Accumulated Deficit $(515,146) $(280,057)

Material Changes vs. Prior Period

  • Significant Increase in Expenses: Total operating expenses increased by 1,085% year-over-year, driven primarily by R&D costs which rose 3,407%. This increase is attributed to the November 2025 asset acquisition, the initiation of the Paragon Option Agreement, and the amortization of the Paramora warrant obligation ($5.0 million).
  • Liquidity Expansion: Cash and cash equivalents increased by $275.3 million, primarily due to a February 2026 underwritten public offering that generated approximately $295.5 million in net proceeds.
  • Capital Structure Changes: Following stockholder approval in February 2026, 42,005 shares of Series C Preferred Stock were automatically converted into 42,005,000 shares of Common Stock. The company also increased its authorized common stock from 300 million to 500 million shares.
  • Portfolio Strategy Shift: In March 2026, the company deprioritized the development of GB3226 to focus exclusively on its mutCALR portfolio (DMR-001, DMR-002, DMR-003).

Guidance, Outlook, and Risks

  • Development Timeline: The company intends to make its first regulatory submission for DMR-001 in mid-2026, with a global Phase 1/1b trial initiation expected thereafter. DMR-002 submission is targeted for the second half of 2026, and DMR-003 for 2027.
  • Liquidity Outlook: Management believes existing cash resources ($532.9 million as of March 31, 2026) are sufficient to fund operations into 2029. However, the company expects to continue incurring losses and will require additional financing in the future.
  • Key Risks:
    • Preclinical Stage: No products have been approved or administered to humans; success is not guaranteed.
    • Third-Party Reliance: Significant reliance on Paragon Therapeutics for research and development under the Paragon Option Agreement, including potential milestone payments up to $22.0 million.
    • Regulatory and Manufacturing: Risks associated with FDA approval, clinical trial enrollment, and reliance on third-party contract manufacturers (including potential impacts from the BIOSECURE Act regarding Chinese suppliers).
    • Capital Requirements: Failure to raise additional capital could force delays or termination of clinical trials.

Investor Verification Checklist

  • Capital Runway: Verify the accuracy of the "into 2029" funding projection given the rapid increase in quarterly burn rate ($20.6 million operating cash burn in Q1 2026).
  • Paragon Agreement Terms: Review the specific milestones and payment triggers under the Paragon Option Agreement, particularly the $22.0 million potential liability and the $5.0 million non-cash warrant expense recognized in Q1.
  • Regulatory Milestones: Monitor the mid-2026 timeline for the Investigational New Drug (IND) submission for DMR-001.
  • ATM Program Utilization: Track the usage of the $150 million At-The-Market (ATM) offering program, noting that $29.4 million was raised in May 2026 (subsequent to the quarter end).
  • Preferred Stock Conversion: Confirm the status of remaining Series C Preferred Stock and any future conversion events that may impact common share dilution.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.